Empresaria Group Regulatory News (EMR)

Hardman & Co issues research report on Empresaria Group

Hardman & Co have published a report on Empresaria Group. Empresaria has announced the acquisition of Pharmaceutical Strategies a provider of temporary workers to the US healthcare sector. The business is currently growing strongly and sector growth is expected to continue. The deal has been financed by a share placing which was oversubscribed and by small additional debt facility. The deal should be earnings enhancing in its first full year and the balance sheet remains in a comfortable position. The vendor's CEO has been locked in and the deal meets a number of the group's strategic objectives. It looks a great deal and should boost the company's growth.

Please click here for the full report:

http://www.hardmanandco.com/system/files/research_papers/Empresaria%2021.10.15a.pdf

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.